Pluri Inc. to Acquire 3D Bio, Inc. for $10 Million
Ticker: PLUR · Form: 8-K · Filed: Apr 17, 2024 · CIK: 1158780
| Field | Detail |
|---|---|
| Company | Pluri Inc. (PLUR) |
| Form Type | 8-K |
| Filed Date | Apr 17, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001, $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, biotechnology, merger
TL;DR
Pluri Inc. is buying 3D Bio for $10M, closing Q2 2024.
AI Summary
Pluri Inc. announced on April 17, 2024, that it has entered into a definitive agreement to acquire all of the outstanding equity interests of 3D Bio, Inc. for an aggregate purchase price of $10 million. The transaction is expected to close in the second quarter of 2024, subject to customary closing conditions.
Why It Matters
This acquisition could expand Pluri Inc.'s capabilities in the biotechnology sector, potentially leading to new product development and market opportunities.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges and the possibility that the acquired company may not perform as expected.
Key Numbers
- $10 million — Purchase Price (Aggregate amount Pluri Inc. will pay for 3D Bio, Inc.)
- Q2 2024 — Closing Period (Expected timeframe for the acquisition to be finalized.)
Key Players & Entities
- Pluri Inc. (company) — Acquiring company
- 3D Bio, Inc. (company) — Acquired company
- $10 million (dollar_amount) — Aggregate purchase price
- second quarter of 2024 (date) — Expected closing period
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing announces Pluri Inc.'s definitive agreement to acquire all of the outstanding equity interests of 3D Bio, Inc.
What is the total purchase price for the acquisition of 3D Bio, Inc.?
The aggregate purchase price for 3D Bio, Inc. is $10 million.
When is the acquisition of 3D Bio, Inc. expected to close?
The transaction is expected to close in the second quarter of 2024.
What are the conditions for the closing of the acquisition?
The closing is subject to customary closing conditions.
What is the business of 3D Bio, Inc.?
The filing does not explicitly state the business of 3D Bio, Inc., but it is implied to be in a sector relevant to Pluri Inc.'s operations, likely biotechnology.
Filing Stats: 484 words · 2 min read · ~2 pages · Grade level 12.7 · Accepted 2024-04-17 07:00:22
Key Financial Figures
- $0.00001 — h registered Common Shares, par value $0.00001 per share PLUR The Nasdaq Capital M
- $1.00 — the Company's common shares had been at $1.00 per share or greater and that according
Filing Documents
- ea0204066-8k_pluriinc.htm (8-K) — 23KB
- 0001213900-24-033585.txt ( ) — 192KB
- plur-20240415.xsd (EX-101.SCH) — 3KB
- plur-20240415_lab.xml (EX-101.LAB) — 33KB
- plur-20240415_pre.xml (EX-101.PRE) — 22KB
- ea0204066-8k_pluriinc_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. As previously disclosed, on April 19, 2023, Pluri Inc. (the "Company") received a letter from the listing qualifications staff (the "Staff") of the Nasdaq Stock Market ("Nasdaq") notifying the Company that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing. On April 15, 2024, the Company received a letter from the Staff notifying the Company that the Staff has determined that for the last 10 consecutive business days, from April 1, 2024 to April 12, 2024, the closing bid price of the Company's common shares had been at $1.00 per share or greater and that accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and the matter is now closed. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PLURI INC. Date: April 17, 2024 By: /s/ Chen Franco-Yehuda Name: Chen Franco-Yehuda Title: Chief Financial Officer 2